The right chance for temozolomide in metastatic colorectal cancer?
暂无分享,去创建一个
[1] G. Pruneri,et al. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] A. Bardelli,et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] E. Valtorta,et al. Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience , 2017, Targeted Oncology.
[4] T. Cenci,et al. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation , 2017, British Journal of Cancer.
[5] J. Guinney,et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer , 2017, Nature Reviews Cancer.
[6] A. Bardelli,et al. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. , 2017, European journal of cancer.
[7] M. Esteller,et al. Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] F. D. De Braud,et al. Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer , 2016, Targeted Oncology.
[9] M. Gariboldi,et al. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] M. Esteller,et al. Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal Cancer , 2013, Clinical Cancer Research.
[11] J. Tabernero,et al. Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials , 2012, Molecular Cancer Therapeutics.
[12] J. Herman,et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. , 2000, Cancer research.
[13] J. Herman,et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.